Invivyd, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.5817 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 171.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Details
| Name | Invivyd, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 122 |
| Founded | 2020 |
| Ipo Date | 2021-08-06 |
| Ceo | Marc Elia |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US00534A1025 |
| Cusip | 00534A102 |
| Cik | 1832038 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Marc William Elia | Chief Executive Officer and Chairperson of the Board |
| William E. Duke Jr., M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Jill Andersen J.D. | Chief Legal Officer and Corporate Secretary |
| Timothy Lee | Chief Commercial Officer |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Kristie Coneys Kuhl J.D. | Chief Communications Officer |
| Julie Green M.B.A. | Chief Human Resources Officer |
| Rachael Gerlach Ph.D. | Senior Vice President of Regulatory Affairs |
| Katie Falzone CPA | Senior Vice President of Finance |
| Dr. Michael J. Mina M.D., Ph.D. | Chief Medical Officer and Chief Epidemiologist |
Contact
| Address | 205 Church Street, New Haven, Connecticut 06510, United States |
| Phone | (781) 819-0080 |
| Website | https://www.invivyd.com |